AUG 10, 2026 · PHASE 3 TRIAL
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
ClinicalTrials.gov
This is a Phase 3 trial registration with no results posted; the study is still recruiting and has not yet reported outcomes.
Reported
Planned enrollment3680
PhasePHASE 3
Primary outcome measureBreast cancer event-free survival (BC-EFS),…